Table 1.
Degree of insulitis in RM 153-treated NOD mice
| Degree of insulitis (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Treatment | Duration | n | 0 | 1 | 2 | 3 | 4 | Insulitis score |
| Ctr IgG | 2–10 week | 5 | 4·6 | 3·1 | 14·1 | 22·7 | 55·7 | 3·2 ± 0·06 |
| RM153 | 2–10 week | 5 | 30·5 | 23 | 20 | 20 | 6·4 | 1·5 ± 0·43* |
| RM153 (Fab/)2 | 2–10 week | 5 | 27 | 16·6 | 20·9 | 22·9 | 12·42 | 1·8 ± 0·22* |
| RM153 | 4–10 week | 5 | 21·4 | 17·6 | 11 | 23·5 | 26·3 | 2·2 ± 0·52* |
RM153 mAb or control IgG was i.p. injected twice a week during 2–10 and 4–10 week of age. Five nondiabetic mice of each group mAb or control IgG (Ctr IgG) were killed at 30 week of age for histological examination. At least 20 islets per mice were examined for degree of insulitis as described in Materials and Methods. Insulitis score is expressed as mean ± SD.
*
P < 0·01 versus control IgG group (Mann–Whitney U-test).